Zhejiang Medicine Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 5,417

Employees

  • Stock Symbol
  • 600216

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $1.53
  • (As of Friday Closing)

Zhejiang Medicine General Information

Description

Zhejiang Medicine Co Ltd is engaged in the Nutritional supplements, pharmaceutical manufacturing products, and pharmaceutical commerce.

Contact Information

Website
www.zmc.top
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Number 168, Zhiyuan Middle Avenue
  • Binhai New
  • Shaoxing, Zhejiang 312366
  • China
+86 0575
Primary Industry
Pharmaceuticals
Stock Exchange
SHG
Corporate Office
  • Number 168, Zhiyuan Middle Avenue
  • Binhai New
  • Shaoxing, Zhejiang 312366
  • China
+86 0575

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zhejiang Medicine Stock Performance

As of 20-Nov-2026, Zhejiang Medicine’s stock price is $1.53. Its current market cap is $1.47B with 962M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.53 $1.56 $1.51 - $2.69 $1.47B 962M 14.8M $0.10

Zhejiang Medicine Financials Summary

As of 30-Sep-2026, Zhejiang Medicine has a trailing 12-month revenue of $1.22B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,387,882 1,607,925 1,959,629 1,382,128
Revenue 1,223,233 1,234,906 1,306,567 1,101,665
EBITDA 80,353 241,987 270,248 155,491
Net Income 91,841 121,449 161,733 60,727
Total Assets 2,198,543 2,013,905 1,889,765 1,802,830
Total Debt 138,939 123,831 102,523 113,061
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Zhejiang Medicine Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Zhejiang Medicine‘s full profile, request access.

Request a free trial

Zhejiang Medicine Patents

Zhejiang Medicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12239613-B2 Preparation method for carotenoid preparation having high bioavailability and high stability Active 18-Mar-2019
US-20220160653-A1 Preparation method for carotenoid preparation having high bioavailability and high stability Active 18-Mar-2019
US-12302931-B2 Solid beverage containing barley leaves and preparation method thereof Active 24-Jan-2019
US-20220095650-A1 Solid beverage containing barley leaves and preparation method thereof Active 24-Jan-2019
US-11696937-B2 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof Active 06-Mar-2018 A61K38/14
To view Zhejiang Medicine’s complete patent history, request access »

Zhejiang Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zhejiang Medicine Investments (5)

Zhejiang Medicine’s most recent deal was a Later Stage VC with Derlead Biotech. The deal was made on 05-Aug-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Derlead Biotech 05-Aug-2022 Later Stage VC Diagnostic Equipment
Natrium Energy 14-Apr-2020 Secondary Transaction - Private Electrical Equipment
Guobang Pharmaceutical 30-Aug-2019 PE Growth/Expansion Pharmaceuticals
Huaxin Environmental Protection 11-Nov-2013 Secondary Transaction - Private Environmental Services (B2B)
Zhejiang Sunmy Bio-Medical 27-Sep-2011 Joint Venture Pharmaceuticals
To view Zhejiang Medicine’s complete investments history, request access »

Zhejiang Medicine ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

32.69 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Zhejiang Medicine’s complete esg history, request access »

Zhejiang Medicine Exits (3)

Zhejiang Medicine’s most recent exit was on 30-Aug-2019 from Guobang Pharmaceutical. The exit was categorized as with 7 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Guobang Pharmaceutical 30-Aug-2019 Completed
  • 7 buyers
Huaxin Environmental Protection 11-Nov-2013 Completed
Zhejiang Sunmy Bio-Medical 27-Sep-2011 Joint Venture Completed
  • 3 buyers
To view Zhejiang Medicine’s complete exits history, request access »

Zhejiang Medicine FAQs

  • When was Zhejiang Medicine founded?

    Zhejiang Medicine was founded in 1997.

  • Where is Zhejiang Medicine headquartered?

    Zhejiang Medicine is headquartered in Shaoxing, China.

  • What is the size of Zhejiang Medicine?

    Zhejiang Medicine has 5,417 total employees.

  • What industry is Zhejiang Medicine in?

    Zhejiang Medicine’s primary industry is Pharmaceuticals.

  • Is Zhejiang Medicine a private or public company?

    Zhejiang Medicine is a Public company.

  • What is Zhejiang Medicine’s stock symbol?

    The ticker symbol for Zhejiang Medicine is 600216.

  • What is the current stock price of Zhejiang Medicine?

    As of 20-Nov-2026 the stock price of Zhejiang Medicine is $1.53.

  • What is the current market cap of Zhejiang Medicine?

    The current market capitalization of Zhejiang Medicine is $1.47B.

  • What is Zhejiang Medicine’s current revenue?

    The trailing twelve month revenue for Zhejiang Medicine is $1.22B.

  • What is Zhejiang Medicine’s annual earnings per share (EPS)?

    Zhejiang Medicine’s EPS for 12 months was $0.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process